Stocktake Sale on now: wide range of books at up to 70% off!
Register      Login
Microbiology Australia Microbiology Australia Society
Microbiology Australia, bringing Microbiologists together
RESEARCH ARTICLE

Imported biologicals: unforeseen biosecurity risks in the laboratory

Annette M Dougall A B , Tim R Brinkley A C and Brian D Clarke A D
+ Author Affiliations
- Author Affiliations

A Biosecurity Animal Division, Australian Government Department of Agriculture, Water and the Environment, Canberra, ACT, Australia

B Email: annette.dougall@awe.gov.au

C Email: tim.brinkley@awe.gov.au

D Email: brian.clarke@awe.gov.au

Microbiology Australia 41(3) 132-135 https://doi.org/10.1071/MA20035
Published: 13 August 2020

Abstract

Imported biological products are ubiquitous necessities of modern life that can pose significant biosecurity risks to Australia. Products produced using animal material are used everywhere from enzymes in cleaning products, to cell lines and bacterial cultures used to produce vaccines and medicines. This article highlights adventitious agents of biologicals and provides an overview of the considerations and regulatory tools administered under the Biosecurity Act 2015 (Commonwealth) to manage these biosecurity risks whilst still facilitating imports of biologicals.

As imported biological products are so common place in our everyday lives and in laboratory settings it is easy to overlook that they are potential vectors for the introduction of significant biosecurity risks into Australia, such as pathogens of biosecurity concern as well as Security Sensitive Biological Agents (SSBA)1. In addition to SSBAs, many of the most significant animal and environment biosecurity risks are listed in the national notifiable disease list of terrestrial animals2 and the interim national priority list of exotic environmental pests, weeds and diseases3. Australia’s strong regulatory framework for imported biologicals considers these unforeseen risks and manages them according to Australia’s Appropriate Level of Protection (ALOP), which is a high level of sanitary and phytosanitary protection aimed at reducing biosecurity risks to a very low level, but not to zero4.


Unforeseen biosecurity risks

In this article, biologicals are considered to be products or goods produced using microorganisms, viruses or components derived from human, animal and plant tissues. These may be produced by biotechnology industries, or used by laboratories for diagnostics, reproductive services, and research and development. Commercial products such as vaccines and/or therapeutics containing materials of biological origin, and the myriad of specialised laboratory reagents may also be considered biologicals. Microorganisms, parasites and infectious agents used as tools for the development of products, imported as, or included within, the final product are also considered as biologicals for the purposes of this article.

Laboratory personnel and scientists frequently consider the risks posed to human health first and foremost when using biologicals in a laboratory. From a biosafety perspective, humans are most obviously at risk though laboratory-acquired infections5. Less obvious, but important, is the risk posed by biologicals to animals, plants and the environment. This lack of awareness can lead to inadvertent mishandling of imported biologicals contaminated with significant adventitious agents. A key role of the Department of Agriculture, Water and the Environment is to consider these unforeseen and unconsidered risks before biologicals are imported and to work with laboratory networks and importers to facilitate the safe and regulated importation of biologicals, allowing critical scientific research and development to be performed in Australia.

Adventitious agents

Adventitious or extraneous agents are microorganisms or infectious agents introduced into the manufacturing process of a biological product6,7. Adventitious agents can be introduced into many stages of product manufacture from source material to final packaging. Although the likelihood of significant adventitious agents being in biologicals is relatively low, the consequences of their establishment in Australia can be extremely high8. Therefore, the department carefully assesses and manages these risks. There have been significant advances in quality control systems and regulation of the production of biologicals that ensure that the majority of biological products used present a managed biosecurity risk; however, there is still a small percentage of these products that may be contaminated with adventitious agents.

Eukaryotic cell culture is one of the most well established routine laboratory practices for introducing and maintaining biosecurity risks associated with biologicals. Contamination with Mycoplasma spp. is common in eukaryotic cell culture9,10, and cross contamination incidents of cell lines, or contamination with other unknown cell lines is also extremely common11. At least 1/3 of immortalised cell lines in cell culture collections are estimated or demonstrated to be either cross-contaminated, or misidentified12,13. According to the register of misidentified cell lines12 between 9% and 15% may be misidentified at the species level; misidentification at the species level introduces additional biosecurity risk as risk management such as adventitious agent testing or country of origin requirements may be incorrectly targeted. Moreover, continuous cell lines can be used for many years and the historical knowledge of the origin can be lost through inaccurate or absent record keeping further complicating an assessment of biosecurity risk. Numerous pathogenic viruses of animals can easily persist in cell lines as undetected adventitious agents, including significant agents of animal biosecurity concern such as bovine diarrhoea disease virus (BVDV)14, bluetongue virus (BTV)15 and porcine circovirus (PCV)16 among many others as well as agents identified as SSBAs, particularly classical swine fever virus (CSFV)17.

CSFV is the causative agent of classical swine fever (also known as hog cholera) and the last outbreak of CSFV in Australia was eradicated in 196118. CSFV is notifiable to the World Organisation of Animal Health (OIE), nationally notifiable throughout Australia2 and considered a Tier 2 SSBA as regulated by the Australian Government Department of Health1. An outbreak in Australia would have significant animal health and economic consequences19. CSFV is known for persistent cell line contamination, specifically of porcine cell lines17,20,21. The source of CSFV cell contamination is most likely through the use of infected source material20. The routine use of porcine trypsin as a dissociative agent for the detachment of adhered cells in culture is also a potential route for the introduction of CSFV as it has been for other porcine viruses22.

An example of biological products of notable animal biosecurity risk is foetal bovine serum. Foetal bovine serum (FBS) is widely used as a cell culture supplement, as well as in the production of other biologicals and directly in reproductive technology. Between 15% and 49% of commercial FBS produced worldwide is estimated to be contaminated with BVDV14,2325, with the likely associated BVDV contamination in cell line collections between 24% and 33%14,26,27. As a persistent adventitious agent of cell culture, detecting BVDV can be difficult due to the non-cytopathic nature of specific strains. Contamination with exotic BVDV is a significant biosecurity risk to Australia. A recent (2018) overseas example is the association of BVDV-1 outbreak in captive Rocky Mountain bighorn sheep after vaccination with a contaminated modified-live BTV-10 vaccine. In this example, there were significant herd mortalities that the authors hypothesise were directly linked to adventitious agents within the vaccine. Retrospective analysis determined that the vaccine was positive for BVDV-128, while the source of the BVDV in this case is unknown, cell lines, source material or sera are the most likely sources of infection.


Managing the animal biosecurity risks of biologicals

The department utilises a range of regulatory tools and information sources as well as risk assessments to manage the animal and human biosecurity risks posed by imported biologicals. Import conditions, import permits and Approved Arrangements are the key regulatory tools available under the Biosecurity Act 2015. All imported biologicals used in the laboratory environment are managed using at least one of these regulatory tools. Most biological products used in Australia, present a well-managed biosecurity risk, however, there is still a possibility that these products can be contaminated with adventitious agents. Wherever possible, the department imposes the minimum regulatory requirements for each type of product. In most cases an import permit is required, involving an application, fees, provision of relevant information about the products and an assessment by the department of the risks posed and any conditions required to mitigate those risks. For most permit assessments for imported biologicals, the department is seeking to be assured the biologicals pose a very low biosecurity risk. When the biosecurity risk is not sufficiently low, wherever possible conditions will be imposed to reduce the risk, including sourcing, treatment, containment within an Approved Arrangement and end-use conditions (Figure 1), to reduce the risk below Australia’s established ALOP of very low.


Figure 1.  Importing biologicals into Australia.
Click to zoom

An Approved Arrangement is a regulatory tool that provides a legally binding agreement between the department and an entity/institution for them to manage biosecurity risks in a defined way. While Approved Arrangements cover a wide variety of activities, including treatment facilities and containment laboratories. An Approved Arrangement sets the criteria that must be met and gives the department oversight of the activities and outcomes undertaken in the Approved Arrangement. The use of an Approved Arrangement allows the department to impose conditions under the Biosecurity Act 2015 and gives the department a high level of assurance that biosecurity risks will be appropriately managed. For importers, this regulatory assurance can broaden the scope for the use of biological materials in Australia. This may include flexibility in the experimental use of exotic infectious agents themselves where the biosecurity risks cannot otherwise be managed outside of an Approved Arrangement.


Conclusions

The Department of Agriculture, Water, and Environment regulates and performs risk assessments on imported biologicals to identify and manage biosecurity risks posed by adventitious agents in imported biologicals according to Australia’s ALOP. Many agents of biosecurity concern and threat are also established adventitious agents of biologicals. This presents challenges to the application of risk management strategies that can be both practical and feasible whilst minimising risk to an appropriate level. Laboratory managers, principal investigators, scientists and regulators have important roles to play in both risk assessment and management, ensuring that the ever-changing biologicals so critical for day-to-day research and development do not become the source of the next significant disease event.

The best source of information regarding biosecurity regulation of imported biologicals is the department’s BICON database: https://bicon.agriculture.gov.au/BiconWeb4.0. Further information about Approved Arrangements is available at: https://www.agriculture.gov.au/import/arrival/arrangements.


Conflicts of interest

The authors declare no conflicts of interest.



Acknowledgements

We thank Dr Beth Cookson, Wayne Terpstra, and Drs Jill Millan, Nicole Drentin, and Lina Tze for helpful discussion and review. All authors are employees of the Australian Department of Agriculture, Water, and the Environment no specific funding was received for this publication.


References

[1]  Department of Health (2020) Security Sensitive Biological Agents. https://www1.health.gov.au/internet/main/publishing.nsf/Content/ssba.htm (updated 4 March 2020).

[2]  Department of Agriculture (2019) National notifiable disease list of terrestrial animals. Canberra: Department of Agriculture, Water and the Environment. https://www.agriculture.gov.au/sites/default/files/documents/notifiable.pdf (updated April 2019).

[3]  Australian Bureau of Agricultural and Resource Economics and Sciences (2019) Interim priority list of exotic environmental pests and diseases Canberra: Department of Agriculture, Water and the Environment. https://www.agriculture.gov.au/biosecurity/environmental/priority-list (updated 4 February 2020).

[4]  Department of Agriculture (2019) Appropriate Level of Protection. Canberra: Department of Agriculture, Water and the Environment. https://www.agriculture.gov.au/biosecurity/risk-analysis/conducting/appropriate-level-of-protection (updated 4 November 2019).

[5]  Wurtz, N. et al. (2016) Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories. Eur. J. Clin. Microbiol. Infect. Dis. 35, 1247–1258.
Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories.Crossref | GoogleScholarGoogle Scholar | 27234593PubMed |

[6]  Klug, B. et al. (2016) Adventitious agents and live viral vectored vaccines: considerations for archiving samples of biological materials for retrospective analysis. Vaccine 34, 6617–6625.
Adventitious agents and live viral vectored vaccines: considerations for archiving samples of biological materials for retrospective analysis.Crossref | GoogleScholarGoogle Scholar | 27317264PubMed |

[7]  World Health Organization. Annex 3 Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. WHO Expert Committee on Biological Standardization, sixty-first report. WHO technical report series; no. 9782013.

[8]  Garner, M.G. et al. (2002) Economic aspects of foot and mouth disease: perspectives of a free country, Australia. Rev. Sci. Tech. 21, 625–635.
Economic aspects of foot and mouth disease: perspectives of a free country, Australia.Crossref | GoogleScholarGoogle Scholar | 12523702PubMed |

[9]  Drexler, H.G. et al. (2002) Mix-ups and mycoplasma: the enemies within. Leuk. Res. 26, 329–333.
Mix-ups and mycoplasma: the enemies within.Crossref | GoogleScholarGoogle Scholar | 11839374PubMed |

[10]  Volokhov, D.V. et al. (2008) Biological enrichment of mycoplasma agents by cocultivation with permissive cell cultures. Appl. Environ. Microbiol. 74, 5383–5391.
Biological enrichment of mycoplasma agents by cocultivation with permissive cell cultures.Crossref | GoogleScholarGoogle Scholar | 18606798PubMed |

[11]  Bairoch, A. (2018) The Cellosaurus, a cell-line knowledge resource. J. Biomol. Tech. 29, 25–38.
The Cellosaurus, a cell-line knowledge resource.Crossref | GoogleScholarGoogle Scholar | 29805321PubMed |

[12]  Capes-Davis, A. et al. (2010) Check your cultures! A list of cross-contaminated or misidentified cell lines. Int. J. Cancer 127, 1–8.
Check your cultures! A list of cross-contaminated or misidentified cell lines.Crossref | GoogleScholarGoogle Scholar | 20143388PubMed |

[13]  Horbach, S.P.J.M. and Halffman, W. (2017) The ghosts of HeLa: how cell line misidentification contaminates the scientific literature. PLoS One 12, e0186281.
The ghosts of HeLa: how cell line misidentification contaminates the scientific literature.Crossref | GoogleScholarGoogle Scholar |

[14]  Uryvaev, L.V. et al. (2012) Contamination of cell cultures with bovine viral diarrhea virus (BVDV). Bull. Exp. Biol. Med. 153, 77–81.
Contamination of cell cultures with bovine viral diarrhea virus (BVDV).Crossref | GoogleScholarGoogle Scholar | 22808499PubMed |

[15]  Eschbaumer, M. et al. (2011) Contamination in bluetongue virus challenge experiments. Vaccine 29, 4299–4301.
Contamination in bluetongue virus challenge experiments.Crossref | GoogleScholarGoogle Scholar | 21557978PubMed |

[16]  Dulac, G.C. and Afshar, A. (1989) Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs. Can. J. Vet. Res. 53, 431–433.
| 2686830PubMed |

[17]  Bolin, S.R. et al. (1994) Detection of a cell line contaminated with hog cholera virus. J. Am. Vet. Med. Assoc. 205, 742–745.
| 7989247PubMed |

[18]  Leslie, E. et al. (2014) Effective surveillance strategies following a potential classical swine fever incursion in a remote wild pig population in North-Western Australia. Transbound. Emerg. Dis. 61, 432–442.
Effective surveillance strategies following a potential classical swine fever incursion in a remote wild pig population in North-Western Australia.Crossref | GoogleScholarGoogle Scholar | 23294519PubMed |

[19]  Garner, M.G. et al. (2001) The expected economic impact of selected exotic diseases on the pig industry of Australia. Rev. Sci. Tech. 20, 671–685.
The expected economic impact of selected exotic diseases on the pig industry of Australia.Crossref | GoogleScholarGoogle Scholar | 11732410PubMed |

[20]  House, J.A. et al. (1988) Characteristics of the porcine kidney cell line IB-RS-2 clone D10 (IB-RS-2 D10) which is free of hog cholera virus. In Vitro Cell. Dev. Biol. 24, 677–682.
Characteristics of the porcine kidney cell line IB-RS-2 clone D10 (IB-RS-2 D10) which is free of hog cholera virus.Crossref | GoogleScholarGoogle Scholar | 2840431PubMed |

[21]  Shimizu, Y. et al. (1969) Porcine kidney cell line persistently contaminated with avirulent swine fever virus. J. Gen. Virol. 4, 625–628.
Porcine kidney cell line persistently contaminated with avirulent swine fever virus.Crossref | GoogleScholarGoogle Scholar | 5816816PubMed |

[22]  Ma, H. et al. (2011) Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines. Vaccine 29, 8429–8437.
Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines.Crossref | GoogleScholarGoogle Scholar | 21835219PubMed |

[23]  Bolin, S.R. et al. (1991) Methods for detection and frequency of contamination of fetal calf serum with bovine viral diarrhea virus and antibodies against bovine viral diarrhea virus. J. Vet. Diagn. Invest. 3, 199–203.
Methods for detection and frequency of contamination of fetal calf serum with bovine viral diarrhea virus and antibodies against bovine viral diarrhea virus.Crossref | GoogleScholarGoogle Scholar | 1655059PubMed |

[24]  Bolin, S.R. and Ridpath, J.F. (1998) Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum. J. Vet. Diagn. Invest. 10, 135–139.
Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum.Crossref | GoogleScholarGoogle Scholar | 9576339PubMed |

[25]  Pinheiro de Oliveira, T.F. et al. (2013) Detection of contaminants in cell cultures, sera and trypsin. Biologicals 41, 407–414.
Detection of contaminants in cell cultures, sera and trypsin.Crossref | GoogleScholarGoogle Scholar | 24071554PubMed |

[26]  Bolin, S.R. et al. (1994) Survey of cell lines in the American Type Culture Collection for bovine viral diarrhea virus. J. Virol. Methods 48, 211–221.
Survey of cell lines in the American Type Culture Collection for bovine viral diarrhea virus.Crossref | GoogleScholarGoogle Scholar | 7989438PubMed |

[27]  Palomares, R.A. et al. (2013) Bovine viral diarrhea virus fetal persistent infection after immunization with a contaminated modified-live virus vaccine. Theriogenology 79, 1184–1195.
Bovine viral diarrhea virus fetal persistent infection after immunization with a contaminated modified-live virus vaccine.Crossref | GoogleScholarGoogle Scholar | 23561853PubMed |

[28]  Fox, K.A. et al. (2019) Bovine viral diarrhea in captive Rocky Mountain bighorn sheep associated with administration of a contaminated modified-live bluetongue virus vaccine. J. Vet. Diagn. Invest. 31, 107–112.
Bovine viral diarrhea in captive Rocky Mountain bighorn sheep associated with administration of a contaminated modified-live bluetongue virus vaccine.Crossref | GoogleScholarGoogle Scholar | 30541417PubMed |


Biographies

Annette Dougall is a Science Officer at the Department of Agriculture, Water and the Environment. She currently works in the Biologicals group within Animal Biosecurity Branch on the biosecurity policy for biologicals imported into Australia. She has significant research background and experience in parasitology and infectious diseases and has made important contributions to several research projects investigating scabies, leishmaniasis, and Staphyloccocus infection at Menzies School of Health Research, Darwin; schistosomiasis, and hookworm at James Cook University, Cairns, and helminth/γ-herpesvirus co-infection at the University of Liège, Belgium.

Tim Brinkley is the Director of the Laboratory & Human Tissues program in the Department of Agriculture, Water and the Environment. Tim is responsible for leading a team that operationalises import conditions to manage biosecurity risks for a range of laboratory related materials. Tim joined the department in 1999 and has had the opportunity to contribute to a wide range of science-based outcomes delivered by the department. Tim undertook his tertiary studies in biology at the Australian National University.

Brian Clarke is a Principal Science Officer at the Department of Agriculture, Water and the Environment and is the leader of the Biologicals group within Animal Biosecurity Branch. He is a virologist with interests in viruses of biosecurity significance, biotechnology and policy.